APVO - CIK 0001671584
Aptevo Therapeutics Inc. (APVO) reported revenue of $3.11M for fiscal year 2022, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2022 | $3.11M | -74.7% |
| FY 2021 | $12.29M | +185.3% |
| FY 2020 | $4.31M | -86.7% |
| FY 2019 | $32.42M | +40.6% |
| FY 2018 | $23.07M | +57.4% |
| FY 2017 | $14.66M | +46.8% |
| FY 2016 | $9.98M | -70.3% |
| FY 2015 | $33.60M | - |
Between fiscal 2015 and fiscal 2022, Aptevo Therapeutics Inc.'s revenue declined from $33.60M to $3.11M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.